drugset
drugset / Trial / NCT01632696

Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors

NCT01632696 ↗

Phase 0 Terminated 11 enrolled Peregrine Pharmaceuticals
NaSingle-groupOpen-labelOther

Summary

Tumor Imaging of I-124 PGN65 in Solid Tumors

Timeline

Start
2012-06
Primary completion
2016-05
Completion
2016-05

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject I-124 PGN650 Unknown — Intravenous

Indications

cancer